![](https://danskbiotek.dk/wp-content/uploads/2024/03/ceestech-logo-new-2-300x98.png)
Cessatech announces superior simulated pain efficacy in children favouring its lead candidate CT001 relative to its active comparators. 14 June 2024
The simulated pain reduction in NRS in children using CT001 was -87%, compared to -52%, -32% and +10%... Read more